Welcome to our dedicated page for CNS Pharmaceuticals SEC filings (Ticker: CNSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CNS Pharmaceuticals SEC filings document the regulatory record for a clinical-stage pharmaceutical company developing therapies for brain and central nervous system cancers. Its filings cover material-event reports, Regulation FD investor presentations, operating and financial updates, clinical and regulatory disclosures, and capital-structure information for its Nasdaq-listed common stock.
The company’s proxy and 8-K filings also describe governance matters, annual-meeting votes, equity-plan amendments, officer appointments, employment agreements and related compensation arrangements. These disclosures frame the company’s formal reporting around pipeline strategy, corporate leadership, stockholder approvals and public-company controls.
CNS Pharmaceuticals, Inc. furnished an investor presentation outlining a new corporate growth strategy led by a recently installed executive team. The company is pivoting to focus on high-value neurology and oncology markets, emphasizing data-driven, capital-efficient development and targeting assets with strong biological rationale and near-term catalysts.
The strategy includes a formal global search for differentiated preclinical and clinical-stage programs, while positioning legacy glioblastoma multiforme programs such as Berubicin and TPI 287 for potential out-licensing. Management highlights neurology and oncology as large, growing therapeutic areas with significant unmet needs and active deal flow.
Faulkner Eric reported acquisition or exercise transactions in this Form 4 filing.
CNS Pharmaceuticals granted Chief Technology Officer Eric Faulkner 9,500 restricted stock units on March 2, 2026. Each unit represents a contingent right to receive one share of common stock. The award was issued in connection with his employment.
The RSUs vest over time: 25% after six months, another 25% after twelve months, and the remaining 50% in twelve quarterly installments thereafter, provided he remains employed on each vesting date. This is a stock-based compensation grant rather than an open-market share purchase.
CNS Pharmaceuticals, Inc. reported that Eric Faulkner, the company’s Chief Technology Officer, has filed an initial insider ownership report on Form 3. This filing establishes his status as an officer subject to insider reporting rules but does not list any share transactions or holdings in the excerpt provided.
O'Loughlin Steve reported acquisition or exercise transactions in this Form 4 filing.
CNS Pharmaceuticals, Inc. reported that Chief Financial Officer Steve O'Loughlin received a grant of 9,500 restricted stock units on March 2, 2026. Each restricted stock unit represents a contingent right to receive one share of the company’s common stock, issued in connection with his employment.
The award vests over time: 25% on the six-month anniversary of the grant date, another 25% on the twelve-month anniversary, and the remaining 50% in twelve quarterly installments thereafter, subject to his continued employment on each vesting date. Following this grant, he holds 9,500 restricted stock units directly.
CNS Pharmaceuticals, Inc. filed an initial ownership report for Chief Financial Officer Steve O'Loughlin. This Form 3 confirms his status as an officer who is subject to insider reporting rules, but does not list any specific stock transactions or changes in ownership.
CNS Pharmaceuticals has appointed Dr. Lynne Kelley as Chief Medical Officer effective March 2, 2026. Her employment agreement includes a base salary of $450,000, an annual bonus target equal to 40% of base salary, and eligibility for future equity grants determined by the board’s Compensation Committee.
Dr. Kelley will also receive an initial grant of 9,500 restricted stock units, vesting 25% after six months, 25% after twelve months, and the remaining 50% in twelve quarterly installments, subject to continued employment. If she is terminated without cause or resigns for good reason, she is entitled to six months of base salary, a pro-rated target bonus, and accelerated vesting of all unvested equity, subject to a release of claims and covenant compliance.
The company also entered into a separation and severance agreement with former Chief Medical Officer Dr. Sandra Silberman, providing severance equal to three months of her current annualized base salary, paid in three monthly installments.
CNS Pharmaceuticals, Inc. is changing its finance leadership, appointing Steve O’Loughlin as Chief Financial Officer effective March 2, 2026, under a new employment agreement. His compensation includes a $450,000 base salary, a target annual bonus equal to 40% of base salary, and eligibility for equity grants. He will also receive 9,500 restricted stock units that vest over roughly three years, starting six months after his start date, and severance and bonus protections if he is terminated without cause or resigns for good reason.
Current Chief Financial Officer Christopher Downs will resign from that role and become Senior Vice President – Finance on March 2, 2026, under a separate agreement providing a $350,000 base salary, a 30% target bonus, equity eligibility, and six months of salary as severance if he is terminated without cause or leaves for good reason.
Stonepine Capital Management and affiliates report a 7.9% passive stake in CNS Pharmaceuticals, Inc. common stock. The group, including Stonepine Capital, L.P., Stonepine GP, LLC and Jon M. Plexico, collectively reports beneficial ownership of 48,827 shares.
The percentage is based on 620,290 shares outstanding as of November 14, 2025, as disclosed by the issuer. All reporting persons have shared voting and dispositive power over the 48,827 shares and no sole power. They certify the holdings are not for the purpose of changing or influencing control of CNS Pharmaceuticals.
CNS Pharmaceuticals, Inc. is appointing Rami Levin as its new Chief Executive Officer and President effective January 1, 2026, following the resignation of John Climaco on December 16, 2025. Levin will also join the Board of Directors on January 1, 2026.
Levin’s employment agreement sets an initial annual base salary of $580,000, a target annual bonus equal to 50% of base salary based on goals set by the Compensation Committee, and eligibility for annual equity grants. He will receive an initial grant of 19,000 restricted stock units, vesting 25% after six months, 25% after twelve months, and the remaining 50% in twelve quarterly installments, subject to continued employment. If terminated without cause or if he resigns for good reason, he is entitled to 12 months of base salary, a target bonus for the post-year-end period, and accelerated vesting of all unvested equity, subject to a release and covenants.
Under a separation agreement, Climaco will receive 12 months of his current annualized base salary in monthly installments, salary through December 31, 2025, his 2025 cash bonus of $319,000 paid over 12 months, and 12 months of employer-paid COBRA premiums, conditioned on his execution and compliance with the agreement.
CNS Pharmaceuticals, Inc. reported results of its 2025 annual stockholder meeting and related corporate changes. Stockholders approved an amendment to the company’s Amended and Restated Articles of Incorporation to increase authorized common stock from 25,000,000 shares to 300,000,000 shares and authorized preferred stock from 416,667 shares to 5,000,000 shares, and the company filed the amendment in Nevada to make these changes effective. They also approved amendments to the 2020 Equity Plan, raising the number of shares of common stock that may be issued under the plan to 115,061 shares.
All director nominees were elected to serve until the 2026 annual meeting, the appointment of MaloneBailey, LLP as independent auditor for the year ending December 31, 2025 was ratified, and executive compensation was approved on an advisory basis. Stockholders recommended holding the advisory say‑on‑pay vote every year, and the board chose an annual frequency in line with that recommendation. As of the October 10, 2025 record date, 574,580 shares of common stock were issued and outstanding, with 204,107 shares represented at the meeting, constituting a quorum.